Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29151411 | 1.00 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL27873808 | 1.00 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL9328369 | 1.00 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL7736725 | 1.00 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL1261033 | 1.00 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL25170777 | 1.00 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL251881 | 0.98 | CYP3A4 (0.62) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL28608720 | 0.96 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL177766 | 0.96 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL11350922 | 0.96 | CYP3A4 (0.60) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455665-B1 | ETHYL OR HEXYL DICHLOROPHOSPHATE OR DICHLOROPHOSPHONATE REACTED WITH A POLYESTER PREPOLYMER | GUILFORD PHARMACEUTICALS INC. | 2002-09-24 | — | — | US | claimed |
| US-20020028911-A1 | Ethyl or hexyl dichlorophosphate or dichlorophosphonate reacted with a polyester prepolymer | EISAI INC. | 2002-03-07 | — | — | US | claimed |
| WO-2002004544-A2 | POLYMERS AND POLYMERIZATION PROCESSES | GUILFORD PHARMACEUTICALS (US) | 2002-01-17 | — | — | WO | claimed |
| EP-4730479-A2 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | Kyoto University (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-20250246685-A1 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | KYOTO UNIVERSITY (JP) | 2025-07-31 | — | — | US | disclosed |
| EP-4428982-A1 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | Kyoto University (JP) | 2024-09-11 | — | — | EP | disclosed |
| CN-118056309-A | Flame-retardant nonaqueous electrolyte and secondary battery using same | 国立大学法人京都大学 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023079988-A1 | FLAME-RETARDANT NON-AQUEOUS ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | 国立大学法人京都大学 | 2023-05-11 | — | — | WO | disclosed |
| US-20050238616-A1 | Compositions for treatment of central nervous system neoplasms, and methods of making and using the same | GUILFORD PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2002005800-A9 | COMPOSITIONS FOR SUSTAINED RELEASE OF ANALGESIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | GUILFORD PHARM INC (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003060799-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM NEOPLASMS, AND METHODS OF MAKING AND USING THE SAME | GUILFORD PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20020041897-A1 | Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same | GUILFORD PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020028911-A1 | Ethyl or hexyl dichlorophosphate or dichlorophosphonate reacted with a polyester prepolymer | EISAI INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2002005800-A2 | COMPOSITIONS FOR SUSTAINED RELEASE OF ANALGESIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | GUILFORD PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002003957-A2 | COMPOSITIONS FOR SUSTAINED RELEASE OF ANTINEOPLASTIC TAXANES, AND METHODS OF MAKING AND USING THE SAME | GUILFORD PHARMACEUTICALS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004544-A2 | POLYMERS AND POLYMERIZATION PROCESSES | GUILFORD PHARMACEUTICALS (US) | 2002-01-17 | — | — | WO | disclosed |
| US-5646111-A | Cyclic peptide antifungal Agents | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996031228-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0736541-A1 | Cyclic hexapeptide antifungal agents | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5010201-A | Process for the preparation of substituted 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050238616-A1 | Compositions for treatment of central nervous system neoplasms, and methods of making and using the same | PMP22, EWSR1, MLLT1 | CYP3A4 4804/4885LPAR3 1506/4885LPAR2 2181/4885 |
| US-20020041897-A1 | Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same | LPXN, PAICS, TYMP | CYP3A4 4147/4885LPAR3 2371/4885LPAR2 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.